GU Cancers 2023 | Enfortumab vedotin plus pembrolizumab for advanced urothelial carcinoma

Daniel P. Petrylak, MD, Yale Cancer Center, New Haven, CT, talks on enfortumab vedotin plus pembrolizumab for advanced urothelial carcinoma which generated positive results in a clinical trial presented at ASCO GU Cancers Symposium 2023. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.